Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $1.04 Million - $2.78 Million
-48,162 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$11.0 - $28.24 $847,957 - $2.18 Million
-77,087 Reduced 61.55%
48,162 $1.21 Million
Q4 2020

Feb 12, 2021

BUY
$10.12 - $13.94 $1.27 Million - $1.75 Million
125,249 New
125,249 $1.5 Million
Q2 2019

Aug 14, 2019

SELL
$8.85 - $12.49 $177,000 - $249,800
-20,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$10.32 - $14.49 $206,400 - $289,800
20,000 New
20,000 $243,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.